| Title | Anti-Golgi complex antibodies during therapy for chronic hepatitis C with pegylated-interferon plus ribavirin | ||
| Authors | P. Aggelopoulou-Tigka1, A. Kapatais1, D. Soufleris1, P. Karagounis1 and S. Chryssou2
1. First Department of Pathology and 2. Department of Microbiology, General Hospital of West Attika, Athens, Greece |
||
| Citation | Aggelopoulou-Tigka, P., Kapatais, A., Soufleris, D., Karagounis, P., Chryssou, S.: Anti-Golgi complex antibodies during therapy for chronic hepatitis C with pegylated-interferon plus ribavirin, Epitheorese Klin. Farmakol. Farmakokinet. 22(1): 65-67 (2008) | ||
| Publication Date | Accepted for publication (Final verson): April 1, 2008 | ||
| Full Text Language | English | ||
| Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)
pharmakonpress[at]pharmakonpress[.]gr |
||
| Keywords | Anti-Golgi complex antibody, HCV, pegylated-IFN-ribavirin. | ||
| Other Terms | Review article | ||
| Summary | Pegylated interferon (Peg-IFN) plus ribavirin is the standard therapy for hepatitis C. Peg-IFN has several antiviral mechanisms, but its role in hepatitis C treatment seems to be related to its immunomodulatory effect. Ribavirin, an antiviral agent, potentiates IFN activity when added to it. Both drugs are associated with adverse reactions of different magnitudes. Autoimmune phenomena have been reported with this treatment. In this paper it is described, in five cases, the presence of anti-Golgi complex antibodies during therapy of HCV. These antibodies could be found as a marker of autoimmune diseases. But in these cases is an autoimmune phenomenon of pegylated interferon plus ribavirin that disappeared after stopping therapy. This phenomenon could be a prognostic marker for the follow up of treatment. | ||
| References | 1. Bruno R., Sacchi P., Ciappina V., et al.: Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis C: A randomized, controlled study. Antiviral Ther. 9: 491-497 (2004)
2. Luxon B.A., Grace M., Brassard D., Bordens R.: Pegylated interferon for the treatment of chronic hepatitis C infection. Clin. Ther. 24: 1363-1383 (2002) 3. Hayden F.G.: Antiviral agents (nonretroviral). In: (L.L. Brunton, J.S. Lazo, K.L. Parker, eds) Goodman and Gilman’s The Pharmacological Basis of Therapeutics. Pp. 1243-1271, 11th Edition, McGRAW-Hill, NewYork, 2006 4. Fried M., Shiftman M., Reddy K., et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347: 975-982 (2002) 5. Hadziyannis S.J., Sette H., Morgan T., et al.: Peg i nterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C.: A randimized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140: 346-355 (2004) 6. Poynard T., McHutch ison J., Manns M. et al.: Impact of pegulated interferin alfa-2b and ribavirin on liver fibrosis in patients 5th chronic hepatitis C. Gastroenterology 82: 1303-1313 (2002) 7. Paraná R., Schinoni M.I., de Freitas I.A.R., Codes L., Cruz M., Andrade Z., Trepo C.: Anti-Golgi complex antibodies during pegylated interferon therapy for hepatitis C. Liver International 26: 1148-1154 (2006) 8. Clifford B.D., Donahue D., Smith L., et al.: High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1997; 26: 561-6 2002; 136: 747-57. 9. Herrmann E., Lee J.H., Marnos G., Mod i M., Zeuzem S.: Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegulated interferon. Hepatology 38: 1351-1358 (2003) 10. Noda K., Enomoto N., Aria K., et al.: Induction of anti-nuclear antibody after interferon therapy in patents with hepatitis type-C infection: its relation to the efficacy of therapy. Scand. J. Gastroenterol. 41: 1672-1677 (1996) 11. Rodriguez J.I., Gelp i C., Thomson M., Real F.L., Fernandez J.: Anti-Golgi complex auto antibodies in a patient with Sjogren syndrome and lymphoma. Clin. Exp. Immunol. 49: 579-586 (1982) 12. Mohan T.C., Jalil H.A., Nadarajah M., Sng E.H.: Four patents in Singapore with anti-Golgi antibodies. Singapore Med. J. 32: 332-334 (1991) 13. Kladney R.D., Cui X., Bulla G.A., Brunt E.M., Fimmel C.J.: Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology 35: 1431-1440 (2002) 14. Mozo L., S i mo A., Suarez A., Rodrigo L., Gutierrez C.: Autoantibodies to Golgi proteins in hepatocellular carcinoma: case report and literature review. Eur. J. Gastroenterol. Hepatol. 14: 771-774 (2002) 15. Serafino A., Vall i M.B., Andreola F., et al.: Suggested role of the Golgi apparatus and endoplasmic reticulum for crucial sites of hepatitis C virus replication in human lymphoblastoid cells infected in vitro. J. Med. Virol. 70(1): 31-41 (2003) |
||
| Relative Papers | |||
Online ISSN 1011-6575
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
- Chemical Abstracts
- Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Συντακτικη Επιτροπή-Editorial Board
| ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2008 – ANNUAL SUBSCRIPTION 2008 | |
| Γλώσσα Πλήρους Κειμένου – Full Text Language | Αγγλικά – English |
| Παραγγελία – Αγορά – Order – Buy | Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)
pharmakonpress[at]pharmakonpress[.]gr |
| Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)
pharmakonpress[at]pharmakonpress[.]gr |
|